Toggle sidebar
定价
登录
Gene Therapies for Retinal Neurodegenerative Diseases and Central Nervous System Disorders
搜索文档
GenSight Biologics Reports Cash Position as of September 30, 2025
Businesswire
·
2025-10-07 16:00
公司现金状况 - 截至2025年9月30日，公司现金及现金等价物总额为60万欧元 [1]
Gene Therapies for Retinal Neurodegenerative Diseases and Central Nervous System Disorders
Gene Therapies
Gene Therapies for Retinal Neurodegenerative Diseases and Central Nervous System Disorders
Gene Therapies
